Table 1 Open in new tab Mean annualized...

Table 1

Mean annualized change in score on the PSPRS

Study	Sample size	Mean disease duration	Mean baseline PSPRS	Mean annual PSPRS decline
Golbe¹⁰	65	3.8	42.0	9.7
Ghosh¹³	16	4.0	32.8	11.3
Josephs¹⁵	28	3.1	36.4	14.7
Litvan¹⁴	27	3.1	33.5	9.1
Street¹²	109	3.4	34.7	8.1
Street¹²	80	3.1	-	8.7
Street¹¹	99	-	-	9.9
Street¹¹	52	-	-	11.6
Street^11a	117	4.5	33.0	9.0
Street^11a	57	3.5	31.3	9.7
Grötsch^16b,c	86	3.0	-	11.1
Bang^17d	241	-	39.1	11.1
Höglinger^18c,d	99	-	37.8	9.5
Tsai^19d	198	-	38.9	9.6
Quattrone^20c,d,e	105	1.4	38.0	10.0
*Boxer*²¹^d	*123*	-	*39.0*	*10.9*
*Tolosa*²²^c	21	*3.04*	*40.4*	*10.4*
Leclair-Visonneau²³	14	3.6	32.1	14.8
Apetauerova²⁴	16	-	39.0	11.8
*Nuebling*²⁵	14	-	*29.7*	*10.8*
*Dam*²⁶^e	*138*	*1.8*	*37.3*	*10.6*

Study	Sample size	Mean disease duration	Mean baseline PSPRS	Mean annual PSPRS decline
Golbe¹⁰	65	3.8	42.0	9.7
Ghosh¹³	16	4.0	32.8	11.3
Josephs¹⁵	28	3.1	36.4	14.7
Litvan¹⁴	27	3.1	33.5	9.1
Street¹²	109	3.4	34.7	8.1
Street¹²	80	3.1	-	8.7
Street¹¹	99	-	-	9.9
Street¹¹	52	-	-	11.6
Street^11a	117	4.5	33.0	9.0
Street^11a	57	3.5	31.3	9.7
Grötsch^16b,c	86	3.0	-	11.1
Bang^17d	241	-	39.1	11.1
Höglinger^18c,d	99	-	37.8	9.5
Tsai^19d	198	-	38.9	9.6
Quattrone^20c,d,e	105	1.4	38.0	10.0
*Boxer*²¹^d	*123*	-	*39.0*	*10.9*
*Tolosa*²²^c	21	*3.04*	*40.4*	*10.4*
Leclair-Visonneau²³	14	3.6	32.1	14.8
Apetauerova²⁴	16	-	39.0	11.8
*Nuebling*²⁵	14	-	*29.7*	*10.8*
*Dam*²⁶^e	*138*	*1.8*	*37.3*	*10.6*

Papers in bold font are based on only PSP-RS subjects. Papers in italicized font are clinical trials results.

^aBased on final diagnosis.

^bPlacebo and treatment groups combined.

^cIncludes subjects from NCT01049399.

^dIncludes subjects from NCT01110720.

^eIncludes subjects from NCT03068468.